Walleye Capital
CPIX icon

Walleye Capital’s Cumberland Pharmaceuticals CPIX Stock Holding History

Walleye Capital’s Portfolio CPIX Stock Details CPIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-70,419
Closed -$298K – 4578
2025
Q1 		$298K Buy
+70,419
New +$292K ﹤0.01% 2958

Other funds holding CPIX

Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
JGC
J. Goldman & Co New York $3.44B AUM 33.82% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $5.69B AUM 60.64% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.29% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Walleye Capital's CPIX Position: Q2 2025 in Review

Walleye Capital sold out of Cumberland Pharmaceuticals (CPIX) in Q2 2025, closing a stake of 70,419 shares — an estimated $298K sold.

Walleye Capital first reported a position in CPIX in Q1 2025 and held it in 1 quarter. The position peaked at $298K in Q1 2025. 31 funds tracked by Wall St. Rank hold CPIX as of Q2 2025.

  • Walleye Capital reported no remaining Cumberland Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
  • Walleye Capital sold 70,419 Cumberland Pharmaceuticals shares in Q2 2025, an estimated $298K.
  • Walleye Capital first reported a position in Cumberland Pharmaceuticals in Q1 2025 and held it in 1 quarter.
  • Walleye Capital's Cumberland Pharmaceuticals position peaked at $298K in Q1 2025.
  • 31 funds tracked by Wall St. Rank held Cumberland Pharmaceuticals as of Q2 2025.

Based on Walleye Capital's 13F filing for Q2 2025, filed 13 Aug 2025.